Join us Thursday 4/24 at 2pm Central Time, as we focus on the valuation range for Ford (F). Register here. HIDE

CytRx (CYTR)

Add to Watchlists
Create an Alert
3.15 -0.05  -1.56% NASDAQ Apr 23, 4:02PM BATS Real time Currency in USD
View Full Chart
CYTR Price Chart
View All News
Edit Sources

CYTR News

View All Events

CYTR Events

Date Type Description
Mar 05 Earnings CytRx Corporation Q4 2013 Earnings Results. Estimate: -0.21.
Oct 29 Earnings CytRx Reports 2013 Third Quarter Financial Results. Estimate: -0.20.
Aug 06 Earnings CytRx Reports 2013 Second Quarter Financial Results. Estimate: -0.21.
Jul 11 Misc AGM Event for CytRx Corporation
May 09 Earnings CytRx Reports 2013 First Quarter Financial Results. Estimate: -0.16.
View All Performance Charts

CYTR Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). CytRx is up 11.70% over the last year vs S&P 500 Total Return up 22.59%, Galena Biopharma down 1.29%, and Agenus down 39.13%.

Get Quote for
Advertisement

Portfolio Strategies Featuring CYTR

Did CytRx make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

CYTR Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: California
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Biological Product (except Diagnostic) Manufacturing
  • NAICS Code: 325414
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.

Recent Quotes

Symbol Price Chg Chg % Market Cap
CYTR 3.15 -0.05 -1.56% 132.67M
Create Watchlist from Quotes
Advertisement

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

required
required
required
required
required
Get Started Now
document.write('');

{{root.upsell.info.feature_headline}}.
Upgrade to {{root.upsell.info.tier_name}}. Start Your YCharts Membership. Start your {{root.upsell.info.tier_name}} Membership

{{root.upsell.info.feature_description}}

{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{root.upsell.info.tier_name}} Member? Sign in here.